IsoRay brachytherapy seeds
This article was originally published in The Gray Sheet
Executive Summary
IsoRay gains 510(k) clearance for its Proxcelan Cesium-131 brachytherapy seeds preloaded into flexible braided strands and surgical mesh. The Aug. 11 clearance includes indications for lung and head and neck tumors as well as tumors in other organs, according to the company. "The FDA's decision will accelerate our strategy to significantly broaden the scope of Cesium-131 cancer treatments well beyond the current major prostate market," says IsoRay CEO Dwight Babcock